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Abstract N-Linked oligosaccharides play many roles in the fate
and functions of glycoproteins. One function is to assist in the
folding of proteins by mediating interactions of the lectin-like
chaperone proteins calnexin and calreticulin with nascent
glycoproteins. These interactions can be prevented by inhibitors
of the K-glucosidases and this causes some proteins to be
misfolded and retained within the endoplasmic reticulum. In
human immunodeficiency virus (HIV) and hepatitis B virus
(HBV) the misfolding of key viral envelope glycoproteins
interferes with the viral life cycle. It has been demonstrated in
an animal model of chronic HBV that glucosidase inhibitors can
alter glycosylation and have anti-viral activity. As the mechanism
of action of K-glucosidase inhibitors is the induction of misfolded
or otherwise defective viral glycoproteins, such inhibitors may be
useful therapeutics for many viruses, especially those which bud
from the endoplasmic reticulum (where protein folding takes
place). For example bovine viral diarrhea virus, a pestivirus akin
to hepatitis C virus, is also extremely sensitive to glucosidase
inhibition.
z 1998 Federation of European Biochemical Societies.
Key words: K-Glucosidase inhibitor; Antiviral agent;
Endoplasmic reticulum
1. Introduction
N-Linked glycosylation is initiated by the cotranslational
transfer of a 14 residue oligosaccharide precursor
(Glc3Man9GlcNAc2) to certain polypeptides which contain
the Asn-xaa-Ser/Thr glycosylation sequon [1]. After transfer
the glycan chain is modi¢ed by a series of reactions within the
endoplasmic reticulum (ER) and Golgi apparatus (Fig. 1).
The ¢rst processing event is the stepwise removal of the ter-
minal glucose residues by the ER K-glucosidases. K-Glucosid-
ase I removes the outer K1,2-linked glucose residue while the
inner two K1,3-linked glucose residues are removed in two
steps by K-glucosidase II. In contrast to many of the other
glycan processing events in the secretory pathway, the remov-
al of the glucose residues is highly e⁄cient. Cells do not nor-
mally secrete glycoproteins containing glucosylated glycan
structures. Indeed, many cell types contain an additional path-
way, the Golgi-endomannosidase pathway, which can remove
glucose residues from glycoproteins that have not been fully
processed within the ER [2]. In the presence of K-glucosidase
inhibitors, this pathway can allow for further Golgi processing
events to occur.
2. ER glucosidase processing allows interactions with chaperone
proteins
The glucosidase reactions allow glycoproteins to interact
with the ER chaperones calnexin and calreticulin [3]. Recent
work has determined that calnexin is a lectin which binds
exclusively to mono-glucosylated glycoproteins independent
of protein conformation (Fig. 2) [4]. Interactions with calnexin
facilitate the correct folding of some but not all glycoproteins.
Monoglucosylated glycoproteins can be formed either by the
sequential action of K-glucosidase I and II or by the action of
the UDP-Glc:glycoprotein glucosyltransferase (Fig. 2) [5],
which can reglucosylate misfolded glycoproteins that have
been processed by K-glucosidase II [6]. This process allows
further interactions with calnexin to occur, and can continue
until the native conformation of the protein is achieved and
the glycoprotein is no longer reglucosylated by the glucosyl-
transferase. For some proteins, such as the vesicular stomatitis
virus (VSV) G protein and in£uenza HA, preventing a calnex-
in interaction with inhibitors of the K-glucosidases causes their
misfolding and prolonged retention within the ER [7]. How-
ever, as not all proteins require a calnexin pathway to achieve
their native conformation, inhibitors of the K-glucosidases can
be used to speci¢cally target the folding of proteins which
require an interaction with calnexin.
3. K-Glucosidase inhibitors as anti-viral agents
Many animal viruses contain an outer envelope which is
composed of one or more viral glycoproteins. These glycopro-
teins are often essential proteins in that they are required in
the viral life cycle, either in virion assembly and secretion and/
or infectivity. As processing of these glycoproteins occurs
through the cellular machinery, inhibitors of the N-glycan
processing pathway have been used to study the role of the
N-glycans in several viral systems including human immuno-
de¢ciency virus (HIV-1 [8]), human hepatitis B virus (HBV
[9]), human cytomegalovirus virus (HCMV [10]), in£uenza
[11], Sinbis virus [12], and VSV [13]. Two examples which
highlight N-linked glycan processing as a target of anti-viral
intervention are the HIV model and the HBV model.
3.1. Glucosidase inhibitors prevent the fusion of HIV
HIV-1, the causative agent of acquired immunode¢ciency
syndrome (AIDS), encodes two essential envelope glycopro-
teins (gp120 and gp41) through endoproteolytic cleavage of a
precursor protein (gp160) within the cis-Golgi apparatus.
Although proteolytically cleaved, gp120 remains non-cova-
lently attached to the lumenal portion of the transmembrane
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gp41 through conserved regions within the amino and car-
boxy terminus. Therefore, gp120 is fully exposed on the outer
face of the viral envelope, with the transmembrane gp41 act-
ing as an anchor for the complex [14]. During infection gp120
binds to the CD4 surface antigen (the cellular receptor) and
undergoes a conformational change and cleavage which ex-
FEBS 20290 29-6-98
Fig. 1. Diagram of some of the major processing events in the biosynthesis of N-linked glycans. N-Linked glycosylation is initiated by the co-
translational transfer of a 14 sugar superstructure to the growing polypeptide. The formation of this superstructure can be inhibited by tunica-
mycin (not shown). Other inhibitors of glycan processing events are shown in the boxes. After transfer to the Golgi, reactions can terminate at
several steps, leading to the secretion of di¡erentially glycosylated proteins (glycoforms). The three major classes of N-linked glycans are shown
at the bottom (complex, hybrid, and oligomannose). Abbreviations are as follows: Glu, glucose; Man, mannose; DNJ, deoxynojirimycin;
NBDNJ, N-butyl-deoxynojirimycin; N-nonyl-DNJ, N-nonyl-deoxynojirimycin; Cast, castanospermine; DMJ, deoxymannojirimycin. For the gly-
can structures (dotted squares): N-acetylglucosamine (GlcNAc); (gray circles): mannose; S : glucose; R : galactose; 8 : sialic acid.
Fig. 2. The actions of glucosidase I and II enable the interactions between folding glycoproteins and the ER chaperones calnexin and calreticu-
lin to occur. K-Glucosidase I cotranslationally removes the terminal K1-2 glucose residue which is followed by the removal of the exposed K1-3
residue by glucosidase II. The resulting monoglucosylated glycoprotein is recognized by and binds to calnexin and/or calreticulin. Removal of
the last K1-3 linked glucose residue mediates release from calnexin. Misfolded proteins can be reglucosylated by the UDP-Glc:glycoprotein glu-
cosyltransferase which allows them to rebind calnexin. Although some glycoproteins appear to require an interaction with calnexin/calreticulin
for their folding and transport out of the ER [7], many do not [28]. In the glycan structures, triangles represent glucose residues.
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poses gp41. The exposure of gp41 allows fusion with the cel-
lular membrane, thus mediating viral entry into the cell [15].
Both gp41 and gp120 are heavily N-glycosylated and nor-
mally contain a mixture of complex and oligomannose type
glycans [14]. Treatment of HIV-1 infected cells with N-butyl-
deoxynojirimycin (NB-DNJ), an inhibitor of the K-glucosid-
ases, inhibits syncytium formation and the formation of in-
fectious virus [16]. In contrast, inhibition of post-ER
glycosylation steps (DMJ, see Fig. 1) had no e¡ect on the
secretion of infectious virus, con¢rming that K-glucosidase
processing is required for proper interactions with calnexin
and/or calreticulin [1].
The reduction in secretion of infectious virus caused by NB-
DNJ is the result of impairments in post-CD4 binding steps
[17]. Although binding to CD4 occurs, the conformational
shift and cleavage of gp120 that results in the exposure of
gp41 does not. Thus, the process of viral fusion is prevented.
Consistent with this is the ¢nding that in the presence of NB-
DNJ there is regional misfolding of gp120. Analysis of gp120
by a panel of conformation-dependent antibodies revealed
structural changes within the V1/V2 loop region of gp120
[18]. Although these changes in gp120 do not prevent the
transport to the plasma membrane or viral budding, they
are su⁄cient to inhibit the viral fusion process, a crucial
step in the HIV life cycle.
3.2. Alterations in the pre-S2 glycan on the HBV M proteins,
using site-directed mutagenesis, tunicamycin or NB-DNJ,
prevents the secretion of hepatitis B virus
In contrast to the HIV envelope glycoproteins, which con-
tain 30 sites of N-linked glycosylation [14], the envelope pro-
teins of hepatitis B virus contain only two glycosylation sites.
However, just as with the HIV envelope proteins, the HBV
glycoproteins are sensitive to inhibitors of the N-linked glyco-
sylation pathway.
Hepatitis B virus, which infects over 350 million people
worldwide, is a major etiological agent of liver disease and
hepatocellular carcinoma [19]. The HBV genome encodes
three envelope proteins: large (L), middle (M) and small
(S). These are derived from a single open reading frame
through the utilization of alternative translational start sites
(see Fig. 3) [20]. In addition to being the major component of
the viral envelope, these proteins are secreted in the form of
smaller non-infectious sub-viral particles. These particles,
which lack DNA, are secreted in vast excess compared to
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Fig. 3. The hepatitis B virus particles and envelope proteins. A: The HBV viral particle consists of a DNA containing nucleocapsid shell which
is enveloped by the HBV envelope proteins. The speci¢c viral envelope glycoproteins are indicated. B: The three HBV envelope proteins with
the site of N-glycan attachment in the pre-S2 and S domains are indicated. The L protein consists of three domains: the pre-S1 domain, pre-S2
domain, and the S domain. M contains the pre-S2 and S domains while the S protein contains only the S domain. All three proteins have a
common N-linked glycosylation site at Asn-146 of the S domain with the M protein containing an additional site at Asn-4 of the pre-S2 do-
main. The Asn-146 glycan site is partially occupied in all three envelope proteins while the pre-S2 site is fully occupied in M but unoccupied in
the L protein [20]. The Asn-4 site on M has been shown to interact with calnexin [24]. C: The hepatitis B surface antigens (HBsAgs) or the
HBV sub-viral particles as they are also called. The shape of the sub-viral particles is dependent upon the relative proportions of the S, M and
L proteins. Spheres are composed predominantly of the S protein with small amounts of the M and L protein. Filaments contain more L pro-
tein and less S protein.
Table 1
HBV viral and sub-viral particle secretion from cells treated with in-
hibitors of the N-linked glycosylation pathway or transfected with
the glycan mutants
Virions Sub-viral particles
Treatment/glycan mutant
Tunicamycina No Yes
NB-DNJb No Yes; No M protein
DMJa Yes Yes
Glycan mutantc
Sg3,Mg3 No Yes
Sg3 Yes Yes
Mg3 No Yes
aAs in [21].
bAs in [9].
cSg3 vector has glycan site Asn-146 removed; Mg3 vector has glycan
site Asn-4 removed; Sg3,Mg3 has both N-linked glycosylation sites
removed (see Fig. 3, [22]).
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the viral particle, often outnumbering the virion a million to
one.
The role of the N-glycans of HBV have been probed with
site-directed mutagenesis and inhibitors of the N-linked gly-
cosylation pathway (Fig. 1). These include tunicamycin (N-
linked glycosylation) [21], NB-DNJ (glucosidase I and II)
[9], and DMJ (mannosidase I) [21]. The results are summa-
rized in Table 1.
Treatment of an HBV secreting cell line (Hep G2.2.15 cells)
with NB-DNJ prevents the secretion of enveloped DNA [9]
and causes the intracellular accumulation of viral DNA and
particles containing excessive amounts of the M protein
[22,23]. In contrast, sub-viral particles containing the L and
S proteins are secreted with a full array of complex glycan
structures which have been processed through the Golgi-en-
domannosidase pathway. In the presence of the glucosidase
blockade, the Golgi-endomannosidase will remove all three
glucose residues in one step [2]. These data show that neither
ER glucosidase processing nor interaction with chaperones
like calnexin, which only recognize monoglucosylated glyco-
proteins, is required for the correct folding of the S or L
proteins.
Site-directed mutagenesis provides evidence that the pre-S2
glycosylation site on M plays an important role in virion
morphogenesis [22]. Viral glycoproteins that lack the pre-S2
glycan site (Mg3) are unable to secrete virus. In contrast,
removal of the common site in the S domain (Sg3) has no
e¡ect on viral secretion. These results, in conjunction with
those seen in Table 1, indicate that the proper folding of
the M protein requires the processing of the pre-S2 glycan
to a Glc1Man9GlcNAc2 structure, which allows it to interact
with calnexin [24]. When this monoglucosylated structure is
prevented from being formed, either by site-directed mutagen-
esis, tunicamycin or NB-DNJ, the M protein does not fold
correctly and viral envelopment is prevented. Consistent with
this is the lack of e¡ect on virus secretion when using DMJ, a
mannosidase inhibitor which prevents the formation of com-
plex glycan structures, but does not interfere with the removal
of the terminal glucose residues by the K-glucosidases nor
with the correct folding of the protein (Table 1 and Figs. 1
and 2). The ¢nding that the inhibition of glycan processing of
a single site can so profoundly in£uence HBV secretion pro-
vides a powerful target for anti-viral intervention.
3.3. Glucosidase inhibitors can be used in an animal model of
HBV to prevent the secretion of virus
Woodchuck hepatitis virus (WHV) is a naturally occurring
hepadnavirus pathogen of woodchucks [25]. WHV shares bio-
chemical properties with human HBV such as (i) glycosylated
envelope proteins, (ii) sensitivity to glucosidase inhibitors in
vitro (unpublished data) and (iii) the capacity to establish
chronic infections in woodchucks which resemble the human
HBV infection in causing chronic hepatitis and hepatocellular
carcinoma [25]. Woodchucks with chronic WHV infection are
well studied and recognized to be good animal models to test
anti-viral agents with potential for treating the human disease.
Recent work has shown that the glucosidase inhibitor N-
nonyl-deoxynojirimycin (N-nonyl-DNJ, see Fig. 1) reduced
the viremia in chronically infected woodchucks in a dose de-
pendent manner [26]. N-Nonyl-DNJ, a 9 carbon alkyl deriv-
ative of deoxynojirimycin (DNJ), is 100^200 times more po-
tent than N-butyl-deoxynojirimycin (NB-DNJ) in inhibiting
HBV in cell based assays (manuscript in preparation). The
mechanism of action of the drug, i.e. the inhibition of gluco-
sidase processing, was observed in N-nonyl-DNJ treated ani-
mals (Fig. 4). Interestingly, at N-nonyl-DNJ concentrations
su⁄cient to prevent WHV secretion the glycosylation of
most serum glycoproteins appears una¡ected (Fig. 4), suggest-
ing that this class of therapeutics is highly selective against
HBV.
Fig. 5 shows that the amount of hyperglucosylated glycan
in the serum correlated with the change in viremia in N-nonyl-
DNJ treated animals. Animals with the highest levels of hy-
perglucosylated glycan were those with the greatest reduction
in viremia. The presence of the hyperglucosylated glycan rep-
resents a biochemical marker which highlights the extreme
sensitivity of HBV to glucosidase inhibitors and can be used
as a measure of drug e⁄cacy.
4. Conclusions and further work
Inhibitors of glycosylation processing for the treatment of
human disease have been used previously [27]. For example,
NB-DNJ has been shown to have anti-HIV properties in vitro
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Fig. 4. Normal phase HPLC pro¢le of serum glycans from an un-
treated animal and a N-nonyl-DNJ treated animal 4 weeks after
treatment. The x-axis shows the retention time of the glycans on
the HPLC column. Note that while after 115 min there are no
peaks in the untreated animal, the treated animal has a small peak
at approximately 116.5 min. This peak, which has been shown by
oligosaccharide sequencing to be the Glc3Man7GlcNAc2 structure,
is indicated. Glucosidase inhibition does not lead to a 100% produc-
tion of the Glc3Man7GlcNAc2 structure due to the presence of a
shunt pathway [2].
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[28] and is tolerated in people [29]. However, problems in
achieving the therapeutic serum concentrations of NB-DNJ
needed to inhibit glucosidase su⁄ciently in humans may limit
the usefulness of the drug as an anti-HIV agent. Furthermore,
glucosidase inhibition does not prevent the secretion of HIV
but rather interferes with the infectivity process. Since one
competent gp120 molecule on the virion surface may be su⁄-
cient to mediate the infection process, total glucosidase inhib-
ition would be required to disrupt the viral life cycle. In HBV,
glucosidase inhibition prevents the formation and secretion of
the virus through the disruption of the viral envelope. In this
case only a few misfolded viral glycoproteins are su⁄cient to
prevent virion formation, and therefore only a mild degree of
glucosidase inhibition is required in vivo to prevent the for-
mation and secretion of virus (see Figs. 4 and 5). In addition,
the use of a derivative, such as N-nonyl-DNJ, which has sig-
ni¢cantly enhanced anti-HBV activity, provides con¢dence
that glycan processing may be a viable therapeutic target
against HBV.
The process of N-linked glycosylation is a dynamic event
which plays many roles in the fate and function of proteins.
One important function is to assistant protein folding through
enabling the interaction with lectin-like chaperones in the ER.
The use of glucosidase inhibitors to prevent these interactions
and have anti-viral activity may be especially promising in
cases where the virus buds through the ER (as in HBV). By
causing the misfolding of only a small number of envelope
glycoproteins, these inhibitors su⁄ciently prevent proper virus
envelopment in the ER and, hence, secretion of virions. Pre-
liminary data obtained with another ER-budding virus (bo-
vine viral diarrhea virus, BVDV) supports this hypothesis
(manuscript in preparation). BVDV is extremely sensitive to
glucosidase inhibitors (Fig. 6). This is particularly interesting
as BVDV is in the same viral family as hepatitis C virus
(HCV) and it is often used as a model for the latter. BVDV
and HCV have a high degree of genomic homology, common
replication strategies, and it is believed the same sub-cellular
location for viral envelopment [30]. If their similarities extend
to the same dependence on a functional glucosidase for the
proper folding of their viral envelope glycoproteins, it may
lead to the exciting possibility that glucosidase inhibitors
could be used as broad based anti viral-hepatitis agents.
Clearly, a single drug against HBV and HCV (and possibly
hepatitis delta virus which uses the HBV glycoproteins) which
together chronically infect over 400 million people worldwide
would be of great therapeutic value.
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Fig. 5. The Glc3Man7GlcNAc2 structure acts as a surrogate marker for drug e⁄cacy. Woodchucks chronically infected with woodchuck hepati-
tis virus (WHV) were treated with N-nonyl DNJ for 4 weeks with varying amounts of drug [26]. The amount of enveloped virus at each week
of treatment was determined and its change, as compared to pre-treatment levels, is shown on the X-axis. The amount of hyperglucosylated
glycan in the serum of treated animals is shown along the Y-axis. Individual animals are indicated by the animal number followed by the week
of glycan analysis (i.e. 231-3 is animal #231 at 3 weeks of treatment). Clearly, it is seen that animals with a greater amount of hyperglucosyl-
ated glycan have the greatest reduction in viremia.
Fig. 6. NB-DNJ prevents plaque formation by bovine viral diarrhea
virus (BVDV). The growth sensitivity of BVDV to the glucosidase
inhibitor NB-DNJ was determined by plaque reduction assay. The
relationship between the number of plaques (as compared to un-
treated) in % of virus remaining (y-axis) and amount of inhibitor
used as a function of the natural log (ln) of the concentration of
drug (in Wg/ml, x-axis) is shown. An 84% reduction in plaques was
achieved using 10 Wg/ml (45 Wm) of NB-DNJ. The IC50 is approxi-
mately 6 Wg/ml (27 Wm). 98% of plaque reduction was achieved with
100 Wg/ml NB-DNJ and even at the highest inhibitor concentration
no cytotoxicity was observed.
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